Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReoPro in Peripheral Arterial Disease (RIO-Trial)
NCT00156611Phase 3Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2002
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing ReoPro + Balloon Angioplasty with Placebo + Balloon Angioplasty (2 arms). Primary endpoint: Prevention of subacute occlusions at 30 days. Status: unknown.
02
Drugs
abciximab
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT00156611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156611.